Plus   Neg

Celgene: Pomalyst Gets Breakthrough Therapy Designation From FDA

Celgene Corp. (CELG) said Monday that the U.S. Food and Drug Administration or FDA has granted Breakthrough Therapy designation to Pomalyst (pomalidomide) for the treatment of patients with human immunodeficiency virus or HIV-positive Kaposi sarcoma who have previously received systemic chemotherapy, as well as patients with HIV-negative Kaposi's sarcoma.

Kaposi sarcoma is a multi-centric tumor caused by Kaposi sarcoma-associated herpesvirus, also called human herpesvirus-8. Patients suffer multiple lesions on the skin and oral mucosa, or on organs such as the lungs or gastrointestinal mucosa. Kaposi sarcoma most commonly arises in persons infected with HIV.

Celegene noted that while the use of combination anti-retroviral treatments such as cART or HAART has reduced the incidence of advanced Kaposi sarcoma in the U.S., there are still nearly 2,000 new cases each year.

The disease is more highly prevalent in areas of the world where HIV treatments are less available, such as sub-Saharan Africa, and in some countries is the most common tumor in men overall.

"The encouraging news of the FDA Breakthrough Therapy designation for POMALYST in Kaposi sarcoma reflects the urgency in accelerating the development of therapies to address diseases of this type. We will continue to work closely with the agency to move this program forward for patients with this rare and serious cancer," said Jay Backstrom, Chief Medical Officer for Celgene.

The FDA granted that Breakthrough Therapy designation on the basis of the results of a clinical study performed under a Cooperative Research and Development Agreement or CRADA by a team led by Dr. Robert Yarchoan, of the HIV and AIDS Malignancy Branch within the Center for Cancer Research of the National Cancer Institutes (NCI).

The results of that study, evaluated Pomalyst in patients with Kaposi sarcoma, with or without HIV infection, many of whom had received prior cytotoxic chemotherapy. The results were published in the Journal of Clinical Oncology.

Celgene said it intends to submit a supplemental New Drug Application for Pomalyst in this disease area by the end of 2019. In addition, the company has two additional studies planned in this disease.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Mountain Rose Herbs has recalled one lot of Fennel Seed Whole after the company found salmonella in part of its inventory. The Eugene, Oregon-based company has recalled all sizes ranging from 4 oz. to 50 lbs. of its Fennel Seed Whole, Lot #25031, because they have the potential to be contaminated... The U.S. Food and Drug Administration announced the suspension of the food facility registration of seafood producer Topway Enterprises Inc., also doing business as Kazy's Gourmet, following repeated food safety violations. From now, Topway will not be able to sell or distribute any food products. Huawei Technologies cut more than 600 jobs at its U.S.-based research and development subsidiary Futurewei Technologies, according to reports. The move comes after the Chinese telecom equipment giant was blacklisted by the U.S. in May this year. Huawei was quoted as saying said that the job cuts, effective July 22, were due to "curtailment of business operations caused by the U.S."
Follow RTT